Publication: Drug Discovery and Development

First reported 5 hours ago - Updated 39 mins ago - 1 reports

AstraZeneca, Roche Collaborate on Companion Diagnostic Test

AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).The companion ... [Published Drug Discovery and Development - 5 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Veloxis Gets EU Marketing Authorization for Transplant Drug

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European ... [Published Drug Discovery and Development - 5 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

COSMOS Results Published on World Hepatitis Day

Medivir AB announced that results from the phase 2 COSMOS clinical study were published in The Lancet , demonstrating that 92% of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained ... [Published Drug Discovery and Development - 5 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Emulate to Commercialize Organs-on-Chips Platform

Emulate Inc. announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms ... [Published Drug Discovery and Development - 5 hours ago]
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

Sorafenib, Capecitabine Combo Fails to Meet Endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary, announced that an investigational Phase 3 trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced breast cancer did not meet its primary endpoint ... [Published Drug Discovery and Development - Jul 25 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Thermo Fisher Scientific Reimagines UHPLC

Thermo Fisher Scientific unveiled a new high performance liquid chromatography system designed from the ground up to provide new levels of performance, productivity and usability when used as a standalone system or with the latest mass spectrometers.The ... [Published Drug Discovery and Development - Jul 26 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

TTP Labtech Technology IDs Novel Drug Candidates for Neuropsychiatric Disorders

The first high-resolution X-ray crystal structure of the metabotropic glutamate receptor 5 (mGlu 5 ) transmembrane domain was reported in Nature this week. The work was performed at Heptares Therapeutics, a leading drug discovery and development company ... [Published Drug Discovery and Development - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Bio-Rad Introduces Bio-Plex Pro RBM Human Metabolic and Hormone Assays

Bio-Rad Laboratories Inc. announced the launch of its new Bio-Plex Pro RBM Human Metabolic and Hormone Assays. Developed in partnership with Myriad RBM, Inc., these multiplex immunoassays permit robust and simultaneous quantification of a highly relevant ... [Published Drug Discovery and Development - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

ChromaTrap Helps Advance Research into Women`s Reproductive Health

An informative video interview with Professor Steve Conlan of the College of Medicine at Swansea University (UK) highlights the latest research developments in women’s reproductive health using unique molecular biology tools.[embedded content]Developed ... [Published Drug Discovery and Development - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

CHMP Recommends MA for Diabetes Drug

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorization for Xultophy for the treatment of type 2 diabetes mellitus ... [Published Drug Discovery and Development - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 1 reports

BMS, Ono Collaborate on Immuno-Oncology

Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of ... [Published Drug Discovery and Development - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Developing Multi-Functional Anti-Inflammatory Drugs

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs). The focus has been on one of the most sought-after pharmaceutical targets in inflammation research: the ... [Published Drug Discovery and Development - Jul 24 2014]

Quotes

Dr Andy Doré, head of Crystallography at Heptares Therapeutics and joint first author of the recent article in Nature , stated, "The mosquito LCP was used for all crystallisation setups of the mGlu 5 -StaR resulting in us obtaining high resolution diffraction quality crystals for this receptor. The ability to reliably dispense low volume boli in 96 well LCP experiments using mosquito LCP is ideal for screening initial conditions and optimising this and other difficult targets."
"We are excited about the positive opinion for Xultophy from the CHMP. We believe that Xultophy represents a new treatment paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk
...Joerg Moeller, member of the Bayer HealthCare Executive Committee and Head of Global Development. "While the primary endpoint of this trial was not met, the results do not affect the currently approved indications for Nexavar. We would like to thank the patients and the study investigators for their contributions and participation in this study."
"We thank the women who participated and the clinical investigators who provided patient care and made this trial possible" Kim said

More Content

All (103) | News (103) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Veloxis Gets EU Marketing Authorization for Tra... [Published Drug Discovery and Development - 5 hours ago]
Emulate to Commercialize Organs-on-Chips Platform [Published Drug Discovery and Development - 5 hours ago]
AstraZeneca, Roche Collaborate on Companion Dia... [Published Drug Discovery and Development - 5 hours ago]
COSMOS Results Published on World Hepatitis Day [Published Drug Discovery and Development - 5 hours ago]
Thermo Fisher Scientific Reimagines UHPLC [Published Drug Discovery and Development - Jul 26 2014]
TTP Labtech Technology IDs Novel Drug Candidate... [Published Drug Discovery and Development - Jul 25 2014]
ChromaTrap Helps Advance Research into Women`s ... [Published Drug Discovery and Development - Jul 25 2014]
Bio-Rad Introduces Bio-Plex Pro RBM Human Metab... [Published Drug Discovery and Development - Jul 25 2014]
CHMP Recommends MA for Diabetes Drug [Published Drug Discovery and Development - Jul 25 2014]
Sorafenib, Capecitabine Combo Fails to Meet End... [Published Drug Discovery and Development - Jul 25 2014]
Developing Multi-Functional Anti-Inflammatory D... [Published Drug Discovery and Development - Jul 24 2014]
BMS, Ono Collaborate on Immuno-Oncology [Published Drug Discovery and Development - Jul 24 2014]
Inovio's HPV Immunotherapy Hits Primary Endpoint [Published Drug Discovery and Development - Jul 23 2014]
Merck Strengthens Commitment to Chinese Market [Published Drug Discovery and Development - Jul 23 2014]
Genes Play a Role in Radiation Survival [Published Drug Discovery and Development - Jul 23 2014]
PSI, AOP Orphan Collaborate on Global Rare Dise... [Published Drug Discovery and Development - Jul 22 2014]
Ganymed Completes Recruitment for Gastroesophag... [Published Drug Discovery and Development - Jul 22 2014]
Easing Drug-Induced Fatty Liver Disease in HIV ... [Published Drug Discovery and Development - Jul 22 2014]
Dipexium Launches Phase 3 Trial of Foot Ulcer A... [Published Drug Discovery and Development - Jul 21 2014]
FDA Accepts Avanir's Trial App for Depression Drug [Published Drug Discovery and Development - Jul 21 2014]
First Patients Enrolled in Trial of Opioid Depe... [Published Drug Discovery and Development - Jul 21 2014]
Researchers Aim to Help Doctors Attack Metastases [Published Drug Discovery and Development - Jul 21 2014]
Combo Therapy Cures Hep C in Co-Infected HIV Pa... [Published Drug Discovery and Development - Jul 21 2014]
Bayer Eye Drug Shows Sustained Vision Improveme... [Published Drug Discovery and Development - Jul 18 2014]
InterMune Gets Breakthrough Therapy Status for ... [Published Drug Discovery and Development - Jul 18 2014]
BMS, Pfizer Launch Phase 4 Eliquis Trial [Published Drug Discovery and Development - Jul 17 2014]
Reoviruses: The Discovery of Their Potential in... [Published Drug Discovery and Development - Jul 17 2014]
Wales Kicks Off Hub to Accelerate Growth in Lif... [Published Drug Discovery and Development - Jul 17 2014]
Pfizer to Acquire InnoPharma for $225M [Published Drug Discovery and Development - Jul 16 2014]
Isis Earns $1M from GSK for Advancing ISIS-TTR Rx [Published Drug Discovery and Development - Jul 16 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.